

# A randomised, double-blind, placebo-controlled trial of Vitamin D supplementation in the management of symptomatic knee osteoarthritis (the VIDEO study)

<b>Submission date</b> 05/04/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 03/05/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 20/03/2017	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

[http://www.ctu.mrc.ac.uk/research\\_areas/study\\_details.aspx?s=43](http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=43)

## Contact information

### Type(s)

Scientific

### Contact name

Dr Richard Keen

### Contact details

Metabolic Unit  
Royal National Orthopaedic Hospital Stanmore  
Brockley Hill  
Stanmore  
United Kingdom  
HA7 4LP

## Additional identifiers

### Protocol serial number

15622

## Study information

Scientific Title

A randomised, double-blind, placebo-controlled trial of Vitamin D supplementation in the management of symptomatic knee osteoarthritis (the VIDEO study)

**Acronym**

VIDEO (VItamin D Evaluation in Osteoarthritis)

**Study objectives**

Vitamin D supplementation may reduce the rate of disease progression and improve symptoms in participants with knee osteoarthritis.

On 29/03/2011 the anticipated end date was changed from 31/01/2009 to 31/08/2011.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised double-blind placebo-controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Knee osteoarthritis

**Interventions**

Participants will be randomised to receive oral vitamin D (as cholecalciferol) 800 IU/day (20 µg /day) or matching placebo tablets.

**Intervention Type**

Supplement

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Vitamin D

**Primary outcome(s)**

Radiological progression of knee OA in medial joint compartment at 36 months

**Key secondary outcome(s)**

1. Radiological progression of knee OA in other joint compartments
2. Reduction in pain and functional disability
3. Improvement in quality of life

**Completion date**

31/08/2011

## Eligibility

**Key inclusion criteria**

1. Participants aged over 50
2. Male or female
3. Ambulatory (not wheelchair bound)
4. Able and willing to attend or comply with treatment and follow-up
5. Radiological evidence of early disease at medial tibio-femoral knee compartment (modified Kellgren & Lawrence [k&l] score 2/3, joint space width [JSW] >1 mm)
6. Pain in knee for most days of previous month
7. Written informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Secondary osteoarthritis (OA), septic arthritis, gout, Wilson's disease, Paget's disease, pseudo gout
2. History of inflammatory arthritis
3. Knee stiffness >30 minutes duration
4. Current user of cod liver oil or vitamin D supplementation
5. Current use of glucosamine or chondroitin for less than 3 months
6. History of hyperparathyroidism or osteomalacia
7. Current use of anti-epileptic medication
8. Current use of bisphosphonates or use within 2 years
9. History of hypercalcaemia or hypercalciuria
10. History of hyperthyroidism, sarcoidosis
11. History of renal stones
12. Previous intra-articular injection: steroid within 3 months, hyalgan within 6 months
13. Previous knee surgery or arthroscopy within 6 months
14. History of osteoporotic fracture
15. History of cancer within last 5 years, excluding skin cancer
16. Serious psychiatric disorders including dementia
17. Inability to understand the procedures
18. Inability to attend or comply with treatment or follow-up scheduling
19. Pregnancy

**Date of first enrolment**

01/02/2004

**Date of final enrolment**

31/08/2011

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Metabolic Unit**

Stanmore

United Kingdom

HA7 4LP

## Sponsor information

**Organisation**

Royal National Orthopaedic Hospital (UK)

**ROR**

<https://ror.org/043j9bc42>

## Funder(s)

**Funder type**

Charity

**Funder Name**

Arthritis Research Campaign 15622

## Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2016		Yes	No
<a href="#">Results article</a>	sub study results	01/09/2017		Yes	No